ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio

LOS ANGELES and LONDON, April 12, 2023 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent and radiopharmaceutical therapies (RPT), is pleased to announce the execution of a new non-exclusive License and Supply…